A breakthrough in antibody research may potentially slow the progression of polycystic kidney disease. The discovery has been characterized as a significant development, with some outlets suggesting it could be a major advancement in treating the condition. The therapy has reportedly received fast track designation from the FDA, although details of the discovery and its implications are still emerging.